DDInter840 DDInter782
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Granisetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Granisetron {u} (Compound) resembles {v} (Compound) Atropine
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
Granisetron {u} (Compound) upregulates {v} (Gene) CASP10
Granisetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Granisetron {u} (Compound) downregulates {v} (Gene) HSPA1A
Granisetron {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Granisetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Granisetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Granisetron (Compound) resembles Hyoscyamine (Compound)
Granisetron (Compound) resembles Atropine (Compound)
Granisetron (Compound) binds CYP3A4 (Gene)
Granisetron (Compound) upregulates CASP10 (Gene)
Granisetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Granisetron (Compound) downregulates HSPA1A (Gene)
Granisetron (Compound) causes Hepatic enzyme increased (Side Effect)
Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Granisetron may cause a minor interaction that can limit clinical effects when taken with Modafinil
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib